Neogen has transformed itself into a much larger, globally scaled diagnostics platform with a strong presence in food and animal safety, areas supported by long-term regulatory and consumer trends. It benefits from a diversified and sticky product portfolio, proprietary technologies, and established customer relationships, all reinforced by consistent R&D investment and a clear focus on innovation. Despite recent turbulence, the business continues to generate positive operating cash flow and retains a liquidity position that, while weaker than before, is still generally sound.

At the same time, the financial picture has deteriorated sharply: profitability has collapsed, large impairment charges have eroded retained earnings, and free cash flow has been negative for several years. Rising leverage and declining cash balances reduce financial flexibility, while integration challenges, elevated overhead, and cost pressures weigh on margins. Competitive and technological risks remain present in a fast-moving diagnostics market, and the sizable write-downs raise concerns about prior capital allocation decisions and the true economic value of acquired assets.

The company’s future hinges on whether it can successfully digest its acquisition, rationalize its cost structure, and translate its strong market position and innovation engine into restored margins and healthier cash flows. Strategic moves under new leadership—such as focusing on core, higher-margin diagnostics and digital solutions—aim to address these issues, but tangible financial improvements may take time to emerge and are not guaranteed. Overall, Neogen appears to have attractive strategic assets and market exposure, paired with a balance sheet and income statement that now require careful rebuilding and disciplined execution.